NEW YORK (GenomeWeb News) – BioFocus will offer its customers Activiomics' proteomics services for identifying novel biomarkers for diagnostics and targets for new drugs, the companies said today.

Under a strategic agreement, BioFocus will offer its customers Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology for proteomics studies in oncology, inflammation, and metabolic disease.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.